跳至主要内容
临床试验/CTRI/2020/12/029739
CTRI/2020/12/029739已完成3 期

A multicentric, randomized, double-blind, parallel, comparative study to demonstrate the non-inferiority of fixed-dose combination of Efonidipine 40 mg and Telmisartan 40 mg tablets to fixed-dose combination of Cilnidipine 10 mg and Telmisartan 40 mg tablets in the management of patients with Stage II hypertension.

Zuventus Healthcare Limited0 个研究点目标入组 240 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
240

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Adults (aged >=18 years) treatment naïve patients.
  • 2. Patients diagnosed with Stage-II hypertension (SBP/DBP: >=160/100 mmHg)
  • 3. Patients willing to sign informed consent

排除标准

  • 1. Patients with known hypersensitivity to angiotensin II receptor blockers or dihydropyridine calcium channel blockers.
  • 2. Patients with history of severe, malignant or secondary hypertension.
  • 3. Patient with cerebrovascular disease in the previous 3 months.
  • 4. Patients with chronic arrhythmia, sick sinus syndrome or sinus bradycardia ( < 50 beats/min).
  • 5. Patients with second- or third-degree atrioventricular block.
  • 6. Female patients who are pregnant, lactating.

研究者

相似试验